50 results on '"Hsiao, Liang-Tsai"'
Search Results
2. Clinical significance of chronic hepatitis B virus infection in patients with primary Sjögren's syndrome.
- Author
-
Chen, Ming-Han, Hsiao, Liang-Tsai, Chen, Ming-Huang, Tsai, Chang-Youh, Huang, Yi-Hsiang, and Chou, Chung-Tei
- Subjects
- *
HEPATITIS B virus , *RHEUMATOID factor , *LIVER diseases , *ANTIGENS , *IMMUNOLOGY , *CIRRHOSIS of the liver , *SJOGREN'S syndrome - Abstract
The role of hepatitis B virus (HBV) infection in patients with primary Sjögren's syndrome (pSS) remains unclear. Therefore, we investigated the prevalence and clinical significance of HBV infection in Taiwanese patients with pSS. One hundred seventy-five patients with pSS who fulfilled the 2002 American-European Revised Classification Criteria were enrolled. Eighteen (10.3%) patients were positive for hepatitis B surface antigen (HBsAg). There were 4 males and 14 females, with the mean age of 54.4 years. The main immunological feature was rheumatoid factor (13 of 18, 72.2%), which was significantly higher than those negative for HBsAg (28.1%, p < 0.001). Twelve (66.7%) patients developed liver dysfunction, which was significantly different from the 15.3% of patients who were negative for HBsAg ( p < 0.001). There was no significant difference in extraglandular features between patients positive and negative for HBsAg, except patients positive for HBsAg had a lower rate to develop pulmonary involvement than those negative for HBsAg (5.6% vs. 29.9%, p = 0.027). The mortality rate of pSS patients positive for HBsAg during follow-up was 12.0% and the presence of HBV infection did not influence the survival rate ( p = 0.730). pSS patients with liver cirrhosis presented shorter median overall survival compared to those with without liver cirrhosis ( p < 0.001). Our findings suggest that HBV infection may protect individuals from pSS and reduce pulmonary involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
3. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.
- Author
-
Hsiao, Liang-Tsai, Yang, Ching-Fen, Yang, Sheng-Hsiang, Gau, Jyh-Pyng, Yu, Yuan-Bin, Hong, Ying-Chung, Liu, Chun-Yu, Liu, Jin-Hwang, Chen, Po-Min, Chiou, Tzeon-Jye, and Tzeng, Cheng-Hwai
- Subjects
- *
KIDNEY diseases , *MULTIPLE myeloma , *THROMBOCYTOPENIA , *BLOOD diseases , *BLOOD plasma - Abstract
Background: Reversal of renal impairment (RI) in patients with multiple myeloma (MM) has been evaluated using the estimated glomerular filtration rate (eGFRMDRD) formula developed by the Modification of Diet in Renal Disease study group. However, the prognostic impact of eGFRMDRD at diagnosis of MM is not well studied, particularly its use in conjunction with the International Staging System (ISS). Methods: Newly diagnosed patients with MM were enrolled between 1996 and 2007. Data on clinical features, laboratory tests, and overall survival were compared in terms of corresponding eGFRMDRD. Results: A total of 387 patients with MM (median age, 71 yr) were enrolled. At diagnosis, 56% had ISS stage III disease; the median values of serum creatinine (SCr) and eGFRMDRD were 1.4 mg/dL and 38.2 mL/min/1.73 m2, respectively. Thirty-four percent of patients had SCr of ≥2.0 mg/dL, and 81.2% had chronic kidney disease stages 3-5 (CKD 3-5). Higher CKD stages were significantly more common in men, older patients (≥65 yr), and those with Durie-Salmon and ISS stage III, light-chain diseases, anemia, thrombocytopenia, hypercalcemia, elevated serum β2 microglobulin, or lactate dehydrogenase. In the Cox regression model, CKD 4-5 or CKD 5 alone was independently associated with poor survival. A diagnosis of CKD 5 was shown to be useful in identifying the subgroup of ISS-III patients at high risk - those with a median overall survival of 7.2 months. Conclusions: Our study demonstrates the prognostic impact of eGFRMDRD in patients with MM and CKD 5 as the ISS-independent surrogate predictor of poorest prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
4. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP.
- Author
-
Lin, Peng-Chan, Hsiao, Liang-Tsai, Poh, Say-Bee, Wang, Wei-Shu, Yen, Chueh-Chuan, Chao, Ta-Chung, Liu, Jin-Hwang, Chiou, Tzeon-Jye, and Chen, Po-Min
- Subjects
- *
OLDER people , *COMMUNICABLE disease treatment , *MYCOSES , *DERMATOMYCOSES , *RITUXIMAB , *REGRESSION analysis , *OPPORTUNISTIC infections , *B cell lymphoma , *DIAGNOSIS , *THERAPEUTICS , *DISEASE risk factors - Abstract
Although adding rituximab to standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is an efficacious and well-tolerated regimen in elderly patients with diffuse large B cell lymphoma (DLBCL), it may increase susceptibility to opportunistic infections, and such cases have been reported. Our study was to identify the risk factors for fungal infection in a retrospective case-control matched study of 34 elderly DLBCL patients treated with rituximab plus CHOP (R-CHOP) and 35 control patients treated with the standard CHOP regimen at the Taipei Veterans General Hospital, Taiwan. The rate of overall infection was similar in both groups. However, subgroup analysis found that the fungal infection rate was significantly different, 41.7 and 17.1%, in the R-CHOP and CHOP groups, respectively, ( P = 0.03). Univariate analysis identified the rituximab plus CHOP chemotherapy regimen ( P = 0.03), age older than 80 years ( P = 0.04), and bone marrow involvement ( P = 0.04) as risk factors for development of fungal infection, whereas, multivariate regression analysis identified only rituximab plus CHOP and old age. Adding rituximab to the standard CHOP regimen in elderly DLBCL patients might increase the incidence of fungal infection especially in those older than 80 years old. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
5. Extended Lamivudine Therapy against Hepatitis B Virus Infection in Hematopoietic Stem Cell Transplant Recipients
- Author
-
Hsiao, Liang-Tsai, Chiou, Tzeon-Jye, Liu, Jin-Hwang, Chu, Chiau-Jun, Lin, Yu-Chen, Chao, Ta-Chung, Wang, Wei-Shu, Yen, Chueh-Chuan, Yang, Muh-Hwa, Tzeng, Cheng-Hwai, and Chen, Po-Min
- Subjects
- *
VIRAL hepatitis , *HEMATOPOIETIC stem cells , *THERAPEUTICS , *LIVER diseases - Abstract
Abstract: Lamivudine has demonstrated efficacy in the treatment and prevention of hepatitis B virus (HBV) reactivation after hematopoietic stem cell transplantation (HSCT). However, most of these studies involved short durations of prophylaxis, so there is significant concern regarding lamivudine resistance in these patients. Between March 1984 and November 2002, 71 HBV surface antigen–positive HSCT recipients, including a subgroup of 16 who received pretransplantation lamivudine therapy, which was continued into the posttransplantation period to prevent reactivation hepatitis, were enrolled onto our study. The efficacy of lamivudine therapy was first evaluated for the subgroup of 16 patients in terms of treatment response, lamivudine resistance, and viral recurrence after discontinuation by using virologic assays. Efficacy was then evaluated for all patients in terms of the hazards of lamivudine therapy for reactivation hepatitis after transplantation. During a median lamivudine therapy period of 73 weeks (range, 19-153 weeks), the initial response showed a median reduction of 2.54 log10 in serum HBV DNA (−0.28 to 6.72 range). Lamivudine-resistant mutations were detected in 10 (63%) of 16 patients during therapy, and 1 (12%) of 16 patients finally developed a viral breakthrough. At a median follow-up of 30 months after discontinuation, 3 (27%) of 11 cases had recurrence of HBV infection. Despite the emergence of the mutations, no deaths were due to HBV reactivation or severe cases of hepatitis. In the Cox proportion regression model regarding reactivation hepatitis after transplantation of all enrolled patients, lamivudine therapy was found to be the only favorable factor for the event, with a hazard ratio of 0.122 (95% confidence interval, 0.016-0.908; P = .040). In conclusion, extended lamivudine therapy is safe and effective for the prevention of HBV reactivation in an HSCT setting and significantly decreases reactivation hepatitis after transplantation. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
6. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma.
- Author
-
Hsiao, Liang-Tsai, Lin, Jen-Tsun, Yu, I-Ting, Chiou, Tzeon-Jye, Liu, Jin-Hwang, Yen, Chueh-Chuan, Wang, Wei-Shu, and Chen, Po-Min
- Subjects
- *
HEPATOCYTE growth factor , *SERUM - Abstract
Abstract: Higher pretreatment serum hepatocyte growth factor (HGF) levels were observed in patients with multiple myeloma and Hodgkin's disease, but not in those with non-Hodgkin's lymphoma (NHL). We examined patients’ serum levels at diagnosis using enzyme-linked immunosorbent assay and histological expression of HGF in pathological specimens of lymphoma, in relation to clinical features. The subjects were 77 NHL patients and 40 healthy controls. The serum levels of HGF in NHL patients at diagnosis were significantly higher than those in healthy controls (median 1019 vs. 689 pg/mL, P < 0.001). At diagnosis, patients with more than two sites of extranodal involvement (P = 0.001), higher scores of international prognostic index (P = 0.015), and advanced Ann Arbor stage (P = 0.023) had a higher level of serum HGF. Although the association of pretreatment serum HGF level and survival was not significant, a correlation of serial change of serum HGF levels with treatment response was found in limited cases. Furthermore, HGF expression of lymphoma tissues was shown in 18 of 24 (75%) different NHL subtypes, including most of the diffuse large B cell lymphoma (12 of 15, 80%). In conclusion, our study showed higher pretreatment serum HGF levels in NHL patients, which was related to clinical features; and the serial change of HGF seemed to parallel the treatment response. The pathogenic role of HGF in NHL patients was further highlighted by a modest expression of HGF in most of the diffuse large B cell lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
7. Stem cell transplant for mantle cell lymphoma in Taiwan.
- Author
-
Wang, Yu-Hung, Hsieh, Ching-Yun, Hsiao, Liang-Tsai, Lin, Tung-Liang, Liu, Yi-Chang, Yao, Ming, Tan, Tran-Der, and Ko, Bor-Sheng
- Subjects
- *
MANTLE cell lymphoma , *STEM cell transplantation , *RITUXIMAB , *ASIANS , *PROGRESSION-free survival , *BONE marrow - Abstract
Mantle cell lymphoma (MCL) is a B-cell lymphoma featuring an aggressive course and a progressive relapsing pattern. International guidelines recommend early consolidative autologous stem cell transplant (auto-SCT) for eligible patients while reserving allogeneic SCT (allo-SCT) as therapy for refractory cases. Since data describing the implementation of transplants in the Asian population with MCL are limited, we aimed to analyze post-SCT outcomes of 99 MCL patients from the Taiwan Bone Marrow Transplant Registry database. The median age was 56 years, and 11% of the patients had blastoid variant MCL. Ninety-four patients received auto-SCT, while 13 patients received allo-SCT, eight of which received allo-SCT after failing auto-SCT. Before auto-SCT, 52% of the patients were in their first complete remission (CR1). Overall, 37 patients (39%) relapsed after auto-SCT. The median post-auto-SCT progression-free survival and overall survival (OS) were 43.6 months and not reached, respectively. Blastoid variant MCL, transplant not received in CR1, and disease progression within 12 months post-auto-SCT independently predicted inferior OS in multivariable analysis. The median post-allo-SCT OS was 74 months. Two patients (15%) died of MCL recurrence post-allo-SCT. Three patients with refractory diseases were salvaged with ibrutinib or venetoclax to allo-SCT. Treatment strategies incorporating novel agents warrant further optimization. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Stevens–Johnson syndrome after treatment with STI571: a case report.
- Author
-
Hsiao, Liang-Tsai, Chung, Hung-Ming, Lin, Jen-Tsun, Chiou, Tzeon-Jye, Liu, Jin-Hwang, Fan, Frank S, Wang, Wei-Shu, Yen, Chueh-Chuan, and Chen, Po-Min
- Subjects
- *
MYELOID leukemia , *SYNDROMES , *PROTEIN-tyrosine kinase inhibitors - Abstract
Summary. Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life-threatening cutaneous reaction, Stevens–Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
9. Acquired hemophilia A in a Taiwanese patient with bullous pemphigoid.
- Author
-
Wang, Ying‐Hsiang, Wu, Wen‐Chi, Hsiao, Liang‐Tsai, Ma, Sheng‐Hsiang, Chen, Chih‐Chiang, and Ho, Yi‐Hsin
- Subjects
- *
BULLOUS pemphigoid , *HEMOPHILIA , *BLOOD coagulation factor VIII antibodies , *BLOOD diseases - Abstract
Dear Editor, Acquired hemophilia A (AHA) is a rare hematologic disease caused by autoantibodies against coagulation factor VIII, which might be idiopathic or linked to malignancy, autoimmune diseases and pregnancy.[1] In the study by Nurul and colleagues, they found that bullous pemphigoid (BP) is a common AHA-associated disorder in Singapore.[2] However, in Taiwan, there was only 1 case reported in 2010.[3] Here, we report another Taiwanese case with BP who developed AHA later and a brief summary of the knowledge to date. In BP patients with AHA, bleeding, including mucocutaneous, muscular, gastrointestinal and retroperitoneal, was the most common presentation.[[2], [4]] As AHA may cause life-threatening hemorrhage, in-time treatment is mandatory, composed of hemostasis and aggressive immunosuppression therapy (IST). For the clinical course, BP usually precedes AHA by a few months, but concurrent events have also been reported.[[4]] Also, there was no strong correlation between AHA occurrence and BP disease activity, as AHA may develop in both stable or relapsed cases.[[4]] In our patient, AHA developed in concordance with flare-up of BP, and kept progressing even as his BP was stabilized. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
10. Allogeneic hematopoietic stem cell transplantation for B‐cell lymphoma in Taiwan.
- Author
-
Lee, Chun‐Hui, Lin, Tzu‐Chien, Yao, Ming, Hsiao, Liang‐Tsai, Ko, Bor‐Sheng, Liu, Chia‐Jen, and Chen, Tsai‐Yun
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *DIFFUSE large B-cell lymphomas , *STEM cell transplantation , *LYMPHOMAS , *GRAFT versus host disease - Abstract
Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is considered for patients with high‐risk B‐cell lymphoma and relapsed or refractory disease. This study aimed to analyze the long‐term follow‐up data of patients who underwent allo‐HSCT in Taiwan. This was a retrospective observational study using data from the Taiwan Society of Blood and Marrow Transplantation database. A total of 105 patients who underwent allo‐HSCT because of high‐risk, relapsed, or refractory disease between 2010 and 2019 were included. Forty‐five percent of the patients previously underwent autologous stem cell transplantation (ASCT). The median follow‐up duration was 18.6 months. The probability of 3‐year progression‐free survival and overall survival (OS) was 34.5% and 37%, respectively. The probability of 1‐year non‐relapse mortality was 31.4%, and the major cause was infection (75.8%). The multivariable analysis showed that not in remission at the time of transplantation and the absence of graft‐versus‐host disease (GVHD) were factors associated with inferior OS. The probability of 3‐year OS in patients with diffuse large B‐cell lymphoma who underwent allo‐HSCT and allo‐HSCT after ASCT was 40.2% and 25.2%, respectively. Allo‐HSCT could be a salvage therapeutic option for relapsed or refractory B‐cell lymphoma. Complete remission at the time of allo‐HSCT and the presence of GVHD are independent variables for overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. The limitations of extracorporeal membrane oxygenation as a bridge to allogeneic hematopoietic stem cell transplantation.
- Author
-
Hsiao, Liang-Tsai, Chung, Fa-Po, Chiou, Tzeon-Jye, Chen, Po-Min, and Tzeng, Cheng-Hwai
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *RESPIRATORY therapy , *ARTIFICIAL respiration , *BRAIN tomography - Abstract
The article describes the case of a 27-year-old male patient who received extracorporeal membrane oxygenation (ECMO) immediately after allogeneic hematopoietic stem cell transplantation (HSCT). In spite of neutrophil engraftment, the patient developed recurrent bacterial infections. Endotracheal intubation was performed on the patient. His brain computed tomography (CT) scan showed hypoxic encephalopathy and intracerebral hemorrhage.
- Published
- 2014
- Full Text
- View/download PDF
12. Fatal Early-Onset Epstein-Barr Virus–Associated Posttransplantation Lymphoproliferative Disease after Successful Adult Dual-Unit Umbilical Cord Blood Transplantation
- Author
-
Poh, Say-Bee, Hsiao, Liang-Tsai, Yang, Ching-Fen, Chiou, Tzeon-Jye, and Chen, Po-Min
- Published
- 2005
- Full Text
- View/download PDF
13. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes.
- Author
-
Chou, Wen‐Chien, Yeh, Su‐Peng, Hsiao, Liang‐Tsai, Lin, Sheng‐Fung, Chen, Yeu‐Chin, Chen, Tsai‐Yun, Laille, Eric, Galettis, Anoula, Dong, Qian, Songer, Steve, and Beach, CL
- Subjects
- *
AZACITIDINE , *MYELODYSPLASTIC syndromes treatment , *DRUG efficacy , *MEDICATION safety , *PHARMACOKINETICS , *HEALTH outcome assessment , *TAIWANESE people , *DISEASES - Abstract
Aim Clinical and pharmacokinetic effects of azacitidine in higher-risk myelodysplastic syndromes were established in mainly Caucasian populations. Because of inter-ethnic genotype variability of drug-metabolizing enzymes, it is important to evaluate azacitidine in populations expected to use the drug. Methods In this single-arm study, Taiwanese patients with higher-risk myelodysplastic syndromes received azacitidine 75 mg/m2/day for 7 days/28-day cycle for up to six cycles. Response-evaluable patients had baseline and cycle 6 marrow assessments. Clinical outcomes are compared descriptively with those from a phase 3 study comprising mainly Caucasian patients ( N = 179). Pharmacokinetics in a subgroup of Taiwanese patients are descriptively compared with a historical control of North American patients ( N = 45). Results Median age of Taiwanese patients ( N = 44) was 64 years (range 36-90), and 46% had poor cytogenetics. Median number of azacitidine cycles was six (1-6). No response-evaluable patient ( n = 33) achieved complete or partial remission; however, 22 patients (50%) achieved hematologic improvement, 12 of 32 patients attained RBC transfusion independence and 7 of 18 attained platelet transfusion independence. Most common grade 3-4 treatment-emergent adverse events were neutropenia (52%) and leukopenia (39%). Pharmacokinetic profiles were similar for Taiwanese ( N = 12) and North American ( N = 45) patients. Maximum plasma concentration was higher in Taiwanese patients; however, mean azacitidine exposure was within the range for North American patients. Conclusion These data confirm the safety and efficacy of azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes. Clinical outcomes were generally comparable with those for Caucasian patients. No meaningful differences in azacitidine pharmacokinetics were observed for Taiwanese patients, and no initial dose adjustment is necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Long‐term outcomes of frontline intensification in primary CNS lymphoma: A real‐world single‐center experience.
- Author
-
Wang, Hao‐Yuan, Yang, Ching‐Fen, Lin, Chia‐Hsin, Hsiao, Liang‐Tsai, Ko, Po‐Shen, Liu, Yao‐Chung, Chiou, Tzeon‐Jye, Chen, Po‐Min, Gau, Jyh‐Pyng, Liu, Jin‐Hwang, and Liu, Chia‐Jen
- Subjects
- *
STEM cell transplantation , *INDUCTION chemotherapy , *AUTOTRANSPLANTATION , *CENTRAL nervous system , *LYMPHOMAS - Abstract
Background: Frontline intensification (including consolidative whole‐brain radiotherapy or high‐dose chemotherapy with autologous stem‐cell transplantation after induction therapy) has been proposed to treat primary central nervous system lymphoma (PCNSL). However, no prospective randomized trials have answered whether frontline intensification can offer a survival benefit to PCNSL patients. We aim to clarify the outcomes and survival influence of frontline intensification on real‐world patients with different risk‐stratified PCNSLs. Methods: Between January 2003 and December 2016, 110 PCNSL adults were retrospectively included, and 76 patients achieved at least PR after induction therapy, including 38 patients who received frontline intensification. The median follow‐up with the 31 survivors was 7.52 years. Results: Of the 38 induction‐completed patients who had not received frontline intensification, 95% achieved post–induction therapy CR/CRu; however, all inevitably recurred. In the 38 who received frontline intensification, CR/CRu improved from 45% (pre‐frontline intensification) to 84% (post‐frontline intensification), and they achieved significantly better PFS (non‐reach vs. 522 days, p < 0.001) and OS (non‐reach vs. 899 days, p < 0.001). Additionally, patients had similar PFS and OS rates when receiving HDC‐ASCT and/or WBRT as frontline intensification. Frontline intensification significantly improved PFS and OS survival in higher‐risk patients (intermediate/high IELSG risk, MSKCC group 2/3, or Nottingham/Barcelona score ≥ 2 points) but did not improve OS in lower‐risk patients. Among the 38 patients who received frontline intensification, two had treatment‐related mortality; 14 recurred after frontline intensification. MTX‐based chemotherapy was the main salvage modality, and the median OS was 295 days after recurrence. Progressive disease and infection (especially pneumonia) are two major causes of mortality in patients who receive frontline intensification. Conclusions: When achieving CR/CRu/PR after induction chemotherapy, frontline intensification should be adopted to improve PFS and OS in real‐world PCNSL patients, especially higher‐risk patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients.
- Author
-
Lin, Wen‐Ying, Tsai, Chun‐Kuang, Yeh, Chiu‐Mei, Chian, Tin, Liu, Yao‐Chung, Wang, Hao‐Yuan, Ko, Po‐Shen, Lin, Ting‐An, Hsiao, Liang‐Tsai, Chen, Po‐Min, Gau, Jyh‐Pyng, and Liu, Chia‐Jen
- Subjects
- *
HERPES zoster , *MULTIPLE myeloma , *STEM cell transplantation , *PREVENTIVE medicine , *OPPORTUNISTIC infections , *HEALTH insurance - Abstract
Background: Multiple myeloma (MM) is known for its immune disturbance and patients suffering from MM are thus vulnerable to opportunistic infections, including herpes zoster (HZ). As HZ infection remarkably affects patients' quality of life and poses huge economic burdens on the health system, we aim to identify the risk factors of HZ infection and evaluate the effects of different dosages, types, and durations of anti‐HZ prophylaxis drugs to prevent HZ infection. Methods: 551 MM patients at Taipei Veterans General Hospital in Taiwan between January 1, 2009 and August 31, 2021 were restrospectively analyzed. The patients' baseline characteristics were recorded. The primary endpoint of the study was the incidence of HZ infection among the studied patient population. Due to the lack of cost coverage from Taiwanese public health insurance on HZ prophylaxis drugs, the use of anti‐HZ drugs mainly depends on physicians' preferences and patients' choices. Results: In our study, prophylaxis was given to 283 of the patients. In the multivariate analysis, we included non‐prophylaxis, age ≥ 60, corrected serum calcium ≥12 mg/dl, serum creatinine ≥2 mg/dl, serum β2‐microglobulin ≥5500 mg/L, autologous stem cell transplant (SCT), and allogeneic SCT for analysis. Our results demonstrated that the non‐prophylaxis group (HR: 2.37, 95% CI 1.57–3.57) and patients receiving autologous SCT (HR: 2.22, 95% CI 1.28–3.86) and allogeneic SCT (HR: 5.12, 95% CI 1.13–23.22) had higher risk of HZ infection. The difference in dosage and types of anti‐HZ drugs showed similar protective effects. In patients who stopped anti‐HZ prophylaxis before active cancer‐related treatment, a higher risk of getting HZ infection compared to the corresponding group was also observed (adjusted HR 3.09, 95% CI 1.35–7.07, p = 0.008). Conclusions: We concluded that MM patients should receive HZ prophylaxis drugs while receiving active cancer‐related treatment. Patients receiving SCT are also at high risk of getting HZ infection, even under prophylaxis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Risk Factors and Outcomes of Stem Cell Mobilization Failure in Multiple Myeloma Patients.
- Author
-
Hsu, Te-Lin, Tsai, Chun-Kuang, Liu, Chun-Yu, Yeh, Chiu-Mei, Lin, Fen-Lan, Hsiao, Liang-Tsai, Liu, Yao-Chung, Wang, Hao-Yuan, Ko, Po-Shen, Lin, Ting-An, Chen, Wen-Chun, Chen, Po-Min, Liu, Jin-Hwang, Gau, Jyh-Pyng, and Liu, Chia-Jen
- Subjects
- *
MULTIPLE myeloma diagnosis , *STATISTICS , *BONE marrow transplantation , *GRANULOCYTE-colony stimulating factor , *HOMOGRAFTS , *CONFIDENCE intervals , *MULTIPLE regression analysis , *MULTIVARIATE analysis , *CANCER chemotherapy , *COLONY-stimulating factors (Physiology) , *LOG-rank test , *RETROSPECTIVE studies , *TREATMENT duration , *TREATMENT failure , *TREATMENT effectiveness , *CANCER patients , *CELL survival , *TUMOR classification , *COMPARATIVE studies , *CELLS , *DESCRIPTIVE statistics , *KAPLAN-Meier estimator , *RESEARCH funding , *MULTIPLE myeloma , *HEMATOPOIETIC stem cell transplantation , *ODDS ratio , *RECEIVER operating characteristic curves , *DATA analysis software , *LONGITUDINAL method , *MONOCYTES , *OVERALL survival , *DISEASE risk factors - Abstract
Introduction: Autologous hematopoietic stem cell transplantation (ASCT) is a well-established treatment for patients with multiple myeloma (MM), and adequate stem cell collection must be assured before ASCT. However, prediction of poor mobilizers (PMs) is still difficult despite several risk factors for mobilization failure having been identified. Methods: We retrospectively analyzed MM patients at Taipei Veterans General Hospital in Taiwan who underwent stem cell collection between October 2006 and August 2020. A CD34+ cell collection of <1 × 106 cells/kg was defined as a mobilization failure. The primary endpoint was mobilization failure. The secondary endpoint was overall survival (OS). Odds ratios (ORs) and 95% confidence intervals (CIs) for mobilization failure were calculated using a logistic regression model. The cumulative incidence of mortality was estimated using the Kaplan-Meier method. Results: In the multivariate analysis, absolute monocyte count <500/µL (adjusted OR 10.75, 95% CI: 1.82–63.57, p = 0.009), platelet count <150,000/µL (adjusted OR 12.49, 95% CI: 2.65–58.89, p = 0.001) before mobilization, and time interval from diagnosis to stem cell harvest ≥180 days (adjusted OR 7.69, 95% CI: 1.61–36.87, p = 0.011) were risk factors for PMs. PM patients had poorer OS compared to patients with successful stem cell collection in the univariate analysis (log-rank test p = 0.027). The predicted probability of PMs was estimated by the multiple logistic regression model with a sensitivity of 84.6% and a specificity of 84.0%. Conclusion: Absolute monocyte count <500/µL, platelet count <150,000/µL, and treatment duration more than 180 days before stem cell mobilization are risk factors for unsuccessful stem cell collection. Our prediction models have high sensitivity and specificity for mobilization failure prediction and allow for early interventions for possible PMs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Acute polymyositis after donor lymphocyte infusion.
- Author
-
Lin, Peng-Chan, Hsiao, Liang-Tsai, and Chen, Po-Min
- Subjects
- *
POLYMYOSITIS , *LYMPHOCYTIC leukemia , *BLOOD cells , *STEM cell transplantation , *IMMUNE system , *SYMPTOMS , *CYCLOSPORINE - Abstract
Lin P-C, Hsiao L-T, Chen P-M. Acute polymyositis after donor lymphocyte infusion.Eur J Haematol 2005: 74: 166–168.© Blackwell Munksgaard 2005.Polymyositis usually occurred along with other manifestations of chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) had been reported. However, polymyositis with a sole manifestation of acute GVHD following donor lymphocyte infusion (DLI) is rare. We reported a 45-yr-old man of acute lymphoid leukemia post-allogeneic HSCT 6 months developed acute polymyositis after DLI. He did not develop any symptoms, signs of acute or chronic GVHD following allogeneic HSCT, despite withdraw of immuosuppresive agents, cyclosporin A (CsA). As the DNA-STR of bone marrow analysis showed mixed chimerism, he received the DLI for remission on May 16, 2002. Acute polymyositis developed following DLI 22 d later. The clinical presentation of polymyositis is compatible with a manifestation of acute GVHD following DLI. It also responds to the treatment of steroid and CsA. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
18. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.
- Author
-
Hsu, Te-Lin, Tsai, Chun-Kuang, Liu, Chun-Yu, Yeh, Chiu-Mei, Lin, Fen-Lan, Hsiao, Liang-Tsai, Liu, Yao-Chung, Chien, Sheng-Hsuan, Wang, Hao-Yuan, Ko, Po-Shen, Lin, Ting-An, Chen, Wen-Chun, Chen, Po-Min, Liu, Jin-Hwang, Gau, Jyh-Pyng, and Liu, Chia-Jen
- Abstract
Multiple myeloma (MM) stands as the second most prevalent hematological malignancy, constituting approximately 10% of all hematological malignancies. Current guidelines recommend upfront autologous stem cell transplantation (ASCT) for transplant-eligible MM patients. This study seeks to delineate factors influencing post–ASCT outcomes in MM patients. Our cohort comprised 150 MM patients from Taipei Veterans General Hospital, with progression-free survival (PFS) as the primary endpoint and overall survival (OS) as the secondary endpoint. A Cox proportional hazards model was employed to discern potential predictive factors for survival. ASCT age ≥ 65 (hazard ratio [HR] 1.94, 95% confidence interval [CI] 1.08–3.47) and the presence of extramedullary disease (HR 2.53, 95% CI 1.53–4.19) negatively impacted PFS. Conversely, treatment response ≥ VGPR before ASCT (HR 0.52, 95% CI 0.31–0.87) and total CD34+ cells collected ≥ 4 × 106 cells/kg on the first stem cell harvesting (HR 0.52, 95% CI 0.32–0.87) were positively associated with PFS. For OS, patients with ISS stage III (HR 2.06, 95% CI 1.05–4.04), the presence of extramedullary disease (HR 3.92, 95% CI 2.03–7.58), light chain ratio ≥ 100 before ASCT (HR 7.08, 95% CI 1.45–34.59), post–ASCT cytomegalovirus infection (HR 9.43, 95% CI 3.09–28.84), and a lower conditioning melphalan dose (< 140 mg/m2; HR 2.75, 95% CI 1.23–6.17) experienced shorter OS. In contrast, post–ASCT day + 15 absolute monocyte counts (D15 AMC) > 500/µl (HR 0.36, 95% CI 0.17–0.79) and post–ASCT day + 15 platelet counts (D15 PLT) > 80,000/µl (HR 0.48, 95% CI 0.24–0.94) were correlated with improved OS. Significantly, early PLT and AMC recovery on day + 15 predicting longer OS represents a novel finding not previously reported. Other factors also align with previous studies. Our study provides real-world insights for post–ASCT outcome prediction beyond clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation.
- Author
-
Lee, Ming-Yang, Chiou, Tzeon-Jye, Hsiao, Liang-Tsai, Yang, Muh-Hwa, Lin, Pang-Chan, Poh, Say-Bee, Yen, Chueh-Chuan, Liu, Jin-Hwang, Teng, Hao-Wei, Chao, Ta-Chung, Wang, Wei-Shu, and Chen, Po-Min
- Subjects
- *
RITUXIMAB , *CYTOMEGALOVIRUS diseases , *HODGKIN'S disease , *HEMATOPOIETIC stem cell transplantation , *MONOCLONAL antibodies , *VIRUS diseases , *B cells - Abstract
The use of monoclonal antibody, rituximab, had been reported to be associated with some severe viral infections. The inference of rituximab therapy and post-transplant cytomegalovirus (CMV) infectious complications in non-Hodgkin’s lymphoma (NHL) patients is still unclear now. From 2002 to 2005, 46 patients with relapsed indolent or high-risk aggressive B cell NHL who received rituximab (17 patients) or not (29 patients) before autologous hematological stem cell transplantation (HSCT) in one institute were retrospectively analyzed for the risk factors of CMV complications after transplantation. Pre-transplant and post-transplant CMV infectious conditions, conditioning regimens, transplant types, and post-transplant complications were recorded. Post-transplant infectious complications were followed up until 6 months after transplantation.Seventeen of 46 patients received rituximab before HSCT. Three of them suffered from CMV infection and two of them developed CMV disease. All of the patients with CMV disease recovered after ganciclovir and CMV-specific immunoglobulin therapy. Twenty-nine of 46 patients without rituximab treatment before HSCT did not have CMV complications after HSCT. The risks to develop CMV infections after autologous HSCT were higher in rituximab-treated patients (17.6% vs 0%, p = 0.045, Fisher exact test, two-sided). The risks to develop CMV diseases had higher trend with rituximab therapy than without rituximab therapy (11.7% vs 0%, p = 0.131, Fisher exact test, two-sided). The NHL patients receiving rituximab therapy had higher risk to develop CMV infectious complications after autologous HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
20. Underweight as a risk factor of mortality in patients with newly diagnosed multiple myeloma.
- Author
-
Tsai, Chun-Kuang, Yeh, Chiu-Mei, Hsu, Te-Lin, Li, Chia-Ju, Tin, Chian, Hsiao, Liang-Tsai, Liu, Yao-Chung, Wang, Hao-Yuan, Ko, Po-Shen, Chen, Po-Min, Liu, Jin-Hwang, Gau, Jyh-Pyng, and Liu, Chia-Jen
- Subjects
- *
MULTIPLE myeloma , *OVERALL survival , *PLASMA cell diseases , *BODY mass index , *MORTALITY , *CLONE cells - Abstract
Purpose: Multiple myeloma (MM), a clonal plasma cell malignancy, composes around 10% of hematologic malignancies. Though recent advances in treatment have dramatically improved MM survival, some aggressive courses of disease and dismal outcomes still exist. Low body weight, undernutrition, and cachexia are noted at MM diagnosis. We aim to evaluate the impact of low body mass index (BMI) and undernutrition in MM patients. Methods: We retrospectively analyzed MM patients at Taipei Veterans General Hospital in Taiwan between January 1, 2006 and October 31, 2018. Being underweight is defined as having a BMI of under 18.5 kg/m2. The patient's baseline characteristics, including BMI, serum albumin level, and comorbidities, etc., were recorded. The primary endpoint of the study was all-cause mortality. A Cox regression model was used to estimate the risk factors of mortality. Results: A total of 378 newly diagnosed MM patients were enrolled in this study. The median age of the patients was 69. Thirty patients (7.9%) were underweight at diagnosis. The median overall survival was 1.3 years (95% CI 0.3–5.7) and 5.0 years (95% CI 3.1–5.9) for patients with low BMI and for patients with normal or higher BMI, respectively. In the multivariate analysis, low BMI (95% CI 1.07–4.44), ECOG ≥2 (95% CI 1.02–2.89), hypoalbuminemia (95% CI 1.21–4.01), high LDH (95% CI 1.22–3.49), and light chain ratio > 100 (95% CI 1.06–2.77) were independent risk factors of mortality. Conclusion: MM patients who were underweight, with hypoalbuminemia, poor performance status, higher LDH, and light chain ratio > 100 were associated with poor overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Risk and impact of invasive fungal infections in patients with multiple myeloma.
- Author
-
Tsai, Chun-Kuang, Liu, Yao-Chung, Kuan, Ai Seon, Lee, Kang-Lung, Yeh, Chiu-Mei, Lee, Yu-Ting, Hsiao, Liang-Tsai, Ko, Po-Shen, Wang, Hao-Yuan, Chen, Po-Min, Liu, Jin-Hwang, Hong, Ying-Chung, Liu, Chia-Jen, and Gau, Jyh-Pyng
- Subjects
- *
MYCOSES , *MULTIPLE myeloma , *STEM cell transplantation , *MONOCLONAL gammopathies , *SERUM albumin , *MULTIVARIATE analysis , *MULTIPLE myeloma treatment , *RESEARCH , *HOMOGRAFTS , *CLINICAL trials , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies - Abstract
Infection is associated with great morbidity and mortality in patients with multiple myeloma (MM), but evidence for invasive fungal infections (IFIs) is lacking. We aimed to investigate risk factors for IFI in MM patients and to determine its impact on patients' survival. We retrospectively analyzed MM patients at Taipei Veterans General Hospital in Taiwan between January 2002 and October 2018. MM was diagnosed according to the International Myeloma Working Group criteria. IFI was defined according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria. All risk factors of IFI in MM patients were estimated using Cox regression models in the univariate and multivariate analyses. Of the 623 patients recruited, 22 (3.5%) were diagnosed with proven or probable IFI. Light chain disease (adjusted hazard ratio [HR] 6.74, 95% confidence interval [CI] 2.10-21.66), hemoglobin less than 8 g/dl (adjusted HR 3.34, 95% CI 1.32-8.42), serum albumin < 3.5 g/dl (adjusted HR 3.24, 95% CI 1.09-9.68), and having received allogeneic stem cell transplantation (allo-SCT) (adjusted HR 5.98, 95% CI 1.62-22.03) were significantly associated with IFI in the multivariate analysis. Contracting IFI was in turn associated with early mortality (adjusted HR 11.60, 95% CI 1.26-106.74). Light chain disease, anemia, hypoalbuminemia, and receiving allo-SCT were independent predictors of IFI in MM patients. The early mortality risk is much higher in those encountering IFI. Physicians must be aware of the rare but potentially lethal infections. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report.
- Author
-
Liu, Yao-Chung, Lin, Ting-An, Wang, Hao-Yuan, Ko, Po-Shen, Liu, Chia-Jen, Hsiao, Liang-Tsai, Chien, Sheng-Hsuan, and Gau, Jyh-Pyng
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *T cells , *EPSTEIN-Barr virus diseases , *ASIANS , *SEZARY syndrome , *CUTANEOUS T-cell lymphoma - Abstract
Background: Extranodal natural killer/T cell lymphoma, nasal type, is one of the more common subtypes of mature T cell lymphoma, especially in the Far East Asian population. This aggressive histologic subtype of peripheral T cell lymphomas is frequently susceptible to exposure of Epstein-Barr virus infection. The optimal treatment is not well elucidated. For stage IV disseminated extranodal natural killer/T cell lymphoma, induction chemotherapy with consolidative autologus or allogeneic hematopoietic stem cell transplantation is recommended as the major first-line treatment. However, there is controversy over which type of chemotherapy is most appropriate and effective as a bridge to autologus or allogeneic hematopoietic stem cell transplantation in patients with newly diagnosed disseminated advanced-stage or relapsed extranodal natural killer/T cell lymphoma because of cancer chemoresistance or associated complications. Pralatrexate is the first US Food and Drug Administration-approved novel agent for the treatment of refractory/recurrent peripheral T cell lymphomas. In our case, pralatrexate was used as a successful bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage disseminated extranodal natural killer/T cell lymphoma refractory to first-line chemotherapy.Case Presentation: We presented a case report of a 29-year-old Asian man diagnosed as having stage IV disseminated extranodal natural killer/T cell lymphoma, nasal type, with skin and bone marrow involvement, whose disease was primary refractory to first-line dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy, but obviously responded to treatment with two cycles of single-agent pralatrexate treatment. Monitoring Epstein-Barr virus viremia revealed dramatic downregulation. In addition to complete remission of the involvement of bone marrow and nasal cavity, skin involvement also obtained partial remission. The extranodal natural killer/T cell lymphoma successfully achieved complete remission after a bridge to allogeneic hematopoietic stem cell transplantation.Conclusions: This is the first study to present pralatrexate as a successful bridge to allogeneic hematopoietic stem cell transplantation in a 29-year-old Asian male patient with advanced-stage extranodal natural killer/T cell lymphoma refractory to first-line dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy. This case provides a novel treatment opinion for extranodal natural killer/T cell lymphoma, especially for the Far East Asian population. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
23. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
- Author
-
Liu, Chia‐Jen, Lin, Shinn‐Yn, Yang, Ching‐Fen, Yeh, Chiu‐Mei, Kuan, Ai‐Seon, Wang, Hao‐Yuan, Tsai, Chun‐Kuang, Gau, Jyh‐Pyng, Hsiao, Liang‐Tsai, Chen, Po‐Min, Liu, Yao‐Chung, Hong, Ying‐Chung, Ko, Po‐Shen, Liu, Jin‐Hwang, and Lin, Chia‐Hsin
- Subjects
- *
PROPORTIONAL hazards models , *DISEASE progression , *CENTRAL nervous system ,CENTRAL nervous system tumors - Abstract
Background: Although various prognostic models for primary central nervous system lymphoma (PCNSL) have been developed, there is no consensus regarding the optimal prognostic index. We aimed to evaluate potential prognostic factors and construct a novel predictive model for PCNSL patients. Methods: We enrolled newly diagnosed PCNSL patients between 2003 and 2015. The primary endpoint was progression‐free survival (PFS), and the secondary endpoint was overall survival (OS). The prognostic factors identified using multivariate Cox proportional hazards models were used to develop a predictive model. We subsequently validated the prognostic model in an independent cohort. We also evaluated the validity of the existing scores: the International Extranodal Lymphoma Study Group (IELSG), the Nottingham/Barcelona (NB), and the Memorial Sloan‐Kettering Cancer Center models (MSKCC). Results: We identified 101 patients with newly diagnosed PCNSL at our center. Multivariate analysis showed that age ≥80, deep brain lesions, and ECOG ≥2 were independent risk factors of PFS. Assigning one point for each factor, we constructed a novel prognostic model, the Taipei Score, with four distinct risk groups (0‐3 points). The performances of the Taipei Score in discriminating both PFS and OS in the training cohort were significant, and the score was validated in the external validation cohort. The IELSG, NB and MSKCC models had insufficient discriminative ability for either PFS or OS in both cohorts. Conclusion: The Taipei Score is a simple model that discriminates PFS and OS for PCNSL patients. The score may offer disease risk stratification and facilitate clinical decision‐making. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia.
- Author
-
Liu, Chia‐Jen, Hong, Ying‐Chung, Kuan, Ai Seon, Yeh, Chiu‐Mei, Tsai, Chun‐Kuang, Liu, Yao‐Chung, Hsiao, Liang‐Tsai, Wang, Hao‐Yuan, Ko, Po‐Shen, Chen, Po‐Min, Liu, Jin‐Hwang, and Gau, Jyh‐Pyng
- Subjects
- *
ACUTE myeloid leukemia , *OLDER patients , *PROPORTIONAL hazards models , *GLOMERULAR filtration rate , *MORTALITY - Abstract
Background: Acute myeloid leukemia (AML) is a common hematologic neoplasm with high incidence and mortality in the elderly. Our aims were to explore risk factors for early mortality in elderly AML patients and develop a new prognostic score. Methods: We enrolled newly diagnosed AML patients age 60 and above at Taipei Veterans General Hospital between July 2008 and May 2017. The primary endpoint was early mortality, defined as death within two months after AML diagnosis. A multivariate Cox proportional hazards model was used to build a risk‐scoring system incorporating significant risk factors for AML. Results: The final cohort included 277 elderly AML patients. The median age was 74 (range 60‐96), and 61.7% were male. The two‐month mortality rate was 29.9%. Age ≥ 80 (adjusted HR 1.88), myocardial infarction (adjusted HR 1.87), ECOG ≥ 2 (adjusted HR 2.10), complex karyotype (adjusted HR 3.21), bone marrow blasts ≥ 70% (adjusted HR 1.88), WBC ≥ 100 × 109/L (adjusted HR 3.31), and estimated glomerular filtration rate (eGFR) < 45 (adjusted HR 2.60) were identified as independent predictors for early mortality in the multivariate analysis. A simplified score incorporating the seven factors was developed with good predictive ability measured by Harrell's C statistic [0.72 (95% CI 0.66‐0.78)]. Conclusions: We identified seven potential risk factors for early mortality and built up a new prognostic score for elderly AML patients. The new score may help clinicians stratify patients and initiate appropriate management. Further validation of our findings on other cohorts is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Primary bone marrow lymphoma: A hematological emergency in adults with fever of unknown origin.
- Author
-
Wang, Hao‐Yuan, Gau, Jyh‐Pyng, Chen, Po‐Min, Liu, Jin‐Hwang, Hsiao, Liang‐Tsai, Yang, Ching‐Fen, Chiou, Tzeon‐Jye, Tsai, Chang‐Youh, Hsu, Hui‐Chi, and Wang, Fu‐der
- Subjects
- *
LYMPHOMAS , *BONE marrow , *LYMPHADENITIS , *PNEUMONIA , *RITUXIMAB - Abstract
Abstract: Primary bone marrow lymphoma (PBML) represents non‐Hodgkin lymphoma (NHL) that primarily arises in the bone marrow (BM) without lymphadenopathy. This condition has various definitions and can be masked by prolonged fever, leading to delayed diagnosis. We aimed to identify clinical features and risk indicators of PBML. We enrolled 269 adults with fever of unknown origin (FUO) who underwent a BM study for potential PBML. Thirty patients were diagnosed with PBML (26 and 4 patients in the training and validation cohort, respectively), and 20 patients (67%) showed initial manifestation of hemophagocytic lymphohistiocytosis (HLH). Among PBML patients in the training cohort, their median overall survival is short (8 days), with pneumonia being the most common direct cause of early mortality, followed by life‐threatening HLH. Despite extremely poor prognoses, some B‐cell PBML patients who survived 30 days after BM studies achieved long‐term survival with rituximab‐based treatment. To assist general practitioners in early PBML diagnosis when approaching adults with naïve FUO, we identified several risk indicators, including elevated serum alkaline‐phosphate levels, lowered serum immunoglobulin‐G levels, cytopenia in ≥2 lineages, and peripheral blood leukoerythroblastosis. Our recently published scoring system, which can predict hematological BM disease in FUO adults, showed excellent ability in recognizing PBML early, with high sensitivity and specificity. We conclude that PBML is a specific “clinical” phenotype of NHL; moreover, we have identified diagnostic clues for early identification of FUO adults with underlying PBML, which should be considered a hematological emergency once suspected in any adult with FUO. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
- Author
-
Ko, Po-Shen, Yu, Yuan-Bin, Liu, Yao-Chung, Wu, Yi-Tsui, Hung, Man-Hsin, Gau, Jyh-Pyng, Liu, Chia-Jen, Hsiao, Liang-Tsai, Chen, Po-Min, Chiou, Tzeon-Jye, Liu, Chun-Yu, and Liu, Jin-Hwang
- Subjects
- *
ANEMIA , *MYELOID leukemia , *IMATINIB , *BENZAMIDE , *PATIENT monitoring , *PROGNOSIS , *CHRONIC myeloid leukemia , *TREATMENT effectiveness , *RETROSPECTIVE studies , *THERAPEUTICS - Abstract
Objectives: This study aimed to examine the prognostic value of anemia for the diagnosis of chronic myeloid leukemia in the chronic phase (CML-CP) receiving imatinib.Methods: One hundred and fifty-four CML-CP patients were enrolled. The influences of moderate anemia with hemoglobin (Hb) < 10 g/dl, four scoring systems, and the early molecular response at 3 months (BCR-ABL ≤10%; 3M-EMR) on the achievement of a deep molecular response (DMR, MR4.5), progression-free survival (PFS), event-free survival (EFS), and overall survival (OS) were compared.Results: Moderate anemia was identified in 44 (28.6%) patients. These patients had more aggressive baseline features and higher risks, as assessed by scoring systems, and less favorable treatment responses vs those without anemia, including 3M-EMR (50.0% vs 69.1%), a complete cytogenetic response at 6 months (20.5% vs 50.9%), and a major molecular response at 12 months (22.5% vs 45.2%), with a median follow-up of 54.0 months. Furthermore, an Hb of 10 g/dl better distinguished DMR, EFS, PFS, and OS than the EUTOS, Sokal, and Hasford scores, and better predicted the responses and survivals in combination with 3M-EMR than 3M-EMR alone.Conclusions: This finding highlights the significance of anemia in CML-CP, and suggests that patients with anemia at diagnosis should be carefully monitored and might benefit from more potent TKIs if not achieving 3M-EMR. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
27. Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.
- Author
-
Chen, Chien-Ting, Liu, Chun-Yu, Yu, Yuan-Bin, Liu, Chia-Jen, Hsiao, Liang-Tsai, Gau, Jyh-Pyng, Chiou, Tzeon-Jye, Liu, Jing-Hwang, and Liu, Yao-Chung
- Subjects
- *
GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *COMPLICATIONS from organ transplantation , *CONFIDENCE intervals , *PATIENTS - Abstract
Chronic graft-versus-host-disease (cGvHD) is a serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Among various organ-specific cGvHD, the cGvHD of liver is less well-characterized. In this study, we applied the National Institutes of Health 2014 scoring criteria of cGvHD to analyze a retrospective cohort of 362 allo-HSCT recipients focusing on cGvHD of liver. The overall incidence of liver cGvHD with a score of 3 by 1.5 years post-transplant was 5.8% (21/362). Poor outcome, in terms of overall survival (OS), were observed in patients with scores of 3 liver cGvHD, comparing to those with scores less than 3 (hazard ratio [HR] 2.037, 95% confidence interval [CI] 1.123–3.696, P = 0.019). In multivariate analysis, male gender (HR 4.004, P = 0.042) and chronic hepatitis C virus (HCV) infection status (HR 19.087, P < 0.001) were statistically significant risk factors for scores of 3 liver cGvHD. Our results indicate that liver cGvHD with scores of 3 has a grave prognosis following allo-HSCT, and that HCV carrier status and male are risk factors. Early recognition of this devastating complication might help in prompt immunosuppressive therapy and reducing late poor outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. Clinical-associated characteristics and microbiological features of bloodstream nontyphoidal salmonella infection in adult patients receiving allogeneic hematopoietic stem cell transplantation.
- Author
-
Ko, Po-Shen, Liu, Yao-Chung, Wang, Hao-Yuan, Wu, Chia-Yun, Fan, Nai-Wen, Liu, Chia-Jen, Yu, Yuan-Bin, Hsiao, Liang-Tsai, Chiou, Tzeon-Jye, Tzeng, Cheng-Hwai, Liu, Jin-Hwang, and Gau, Jyh-Pyng
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *SALMONELLA diseases , *COMPLICATIONS from organ transplantation , *GRAFT versus host disease , *PATIENTS , *CLINICAL trials , *COMPARATIVE studies , *HOMOGRAFTS , *IMMUNOSUPPRESSION , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *SALMONELLA , *SEX distribution , *EVALUATION research ,DISEASES in adults - Abstract
Bloodstream nontyphoidal salmonella (NTS) infection is rare, but its associated characteristics and microbiological features in immunocompromised patients are worth paying attention to, particularly for those receiving allogeneic hematopoietic stem cell transplantation (SCT). No studies so far have analyzed post-transplant bloodstream NTS infection. Therefore, we reviewed 423 adult patients undergoing allogeneic hematopoietic SCT from 2003 to 2014. Nine out of four hundred twenty-three patients (2.13%) developed post-transplant bloodstream NTS infection, including two patients who had subsequent or combined metastatic infections. The median age at SCT was 35 years (interquartile range, 29-46) among the nine patients with bloodstream NTS infection. Male patients were predominant (78%). The median onset of bloodstream NTS infection was at 315 days after SCT (range, 207-629). Multivariate analysis revealed that extensive chronic graft-versus-host disease (GVHD) (OR 8.054, p = 0.003) and nonmyeloablative transplant conditioning (OR 4.604, p = 0.037) were significant associated characteristics for NTS infection. Currently, there are no published data analyzing and exploring post-transplant bloodstream NTS infections in adult allogeneic hematopoietic SCT. Our study determined the associated characteristics and microbiological features for this infection. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. The uniqueness of morphological features of pure erythroid leukemia in myeloid neoplasm with erythroid predominance: A reassessment using criteria revised in the 2016 World Health Organization classification.
- Author
-
Ko, Po-Shen, Liu, Yao-Chung, Yeh, Chiu-Mei, Gau, Jyh-Pyng, Yu, Yuan-Bin, Hsiao, Liang-Tsai, Tzeng, Cheng-Hwai, Chen, Po-Min, Chiou, Tzeon-Jye, Liu, Chia-Jen, and Liu, Jin-Hwang
- Subjects
- *
MYELOID leukemia , *ERYTHROCYTE membranes , *LACTATE dehydrogenase , *MULTIVARIATE analysis - Abstract
We reviewed 97 consecutive cases of myeloid neoplasm with erythroid predominance (MN-EP) between 2000 and 2015. Following 2016 WHO classification, MN-EP patients were classified into four groups. Eight pure erythroid leukemia (PEL) (including t-MN and AML-MRC morphologically fulfilled criteria for PEL) patients had dismal outcomes (median OS: 1 month) and showed more bone marrow fibrosis, worse performance status (PS) and higher serum lactate dehydrogenase (LDH) at diagnosis than the other groups. In the univariate analysis, risks of death in MN-EP patients included the morphologic features of PEL, very poor cytogenetic risk by IPSS-R, bone marrow fibrosis, leukocytosis, anemia, hypoalbuminemia, high LDH, and poor PS. In the multivariate analysis, independent predictors of death were morphologic features of PEL (adjusted hazards ratio [HR] 3.48, 95% confidence interval [CI] 1.24–9.74, p = 0.018), very poor cytogenetic risk by IPSS-R (adjusted HR 2.73, 95% CI 1.22–6.10, p = 0.015), hypoalbuminemia (< 3.7 g/dl) (adjusted HR 2.33, 95% CI 1.10–4.91, p = 0.026) and high serum LDH (≥ 250 U/L) (adjusted HR 2.36, 95% CI 1.28–4.36, p = 0.006). Poor or unfavorable risk in different cytogenetic risk systems independently predicted death and UKMRC-R was the best model. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma.
- Author
-
Chun-Teng Huang, Chia-Jen Liu, Po-Shen Ko, Han-Tsung Liu, Yuan-Bin Yu, Liang-Tsai Hsiao, Jyh-Pyng Gau, Cheng-Hwai Tzeng, Tzeon-Jye Chiou, Jin-Hwang Liu, Muh-Hwa Yang, Ling-Ju Huang, Chun-Yu Liu, Huang, Chun-Teng, Liu, Chia-Jen, Ko, Po-Shen, Liu, Han-Tsung, Yu, Yuan-Bin, Hsiao, Liang-Tsai, and Gau, Jyh-Pyng
- Subjects
- *
SEPSIS , *BLOOD diseases , *MULTIPLE myeloma diagnosis , *IMMUNOCOMPROMISED patients , *IMMUNOGLOBULINS , *DISEASE risk factors , *BACTEREMIA , *MICROBIAL sensitivity tests , *MULTIPLE myeloma , *RETROSPECTIVE studies , *KAPLAN-Meier estimator , *CATHETER-related infections , *ODDS ratio , *DISEASE complications - Abstract
Background: Patients with multiple myeloma are generally immune-compromised either due to pronounced depression in primary antibody responses or because of anti-myeloma therapy. Infection is a major risk factor for early deaths among these patients. The impact of blood stream infections (BSI) on newly diagnosed myeloma patients has been less studied. We aimed to study the incidence and risk factors of BSI within 3 months after diagnosis of multiple myeloma in a tertiary referral center.Methods: Between November 2002 and December 2008, consecutive patients with multiple myeloma in Taipei Veterans General Hospital were retrospectively enrolled. Characteristics of patients with or without BSI were collected. Possible factors associated with development of BSI were analyzed by Cox regression.Results: There were a total of 222 patients. The incidence of BSI within 3 months after diagnosis is 11.7%. The patients with BSI had poorer survival outcomes than those without (mortality rate: 50% vs. 20.9%, p < 0.001). Moreover, advanced International Staging System stage (stage III vs. I/II: odds ratio [OR] 2.69, p = 0.049) and poor Eastern Cooperative Oncology Group (ECOG) performance status (ECOG > 2 vs. ≤ 2: OR 3.58, p = 0.005) were the independent risk factors of BSI, whereas immunoglobulin deficiency and low absolute lymphocyte count were not associated with risk of BSI development.Conclusions: Our study highlights the characteristic of myeloma patients with BSI and the importance of disease and host factors on risk of BSI. Myeloma patients with risks of BSI should be properly managed to reduce early mortality. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
31. Decision-tree algorithm for optimized hematopoietic progenitor cell-based predictions in peripheral blood stem cell mobilization.
- Author
-
Wu, Chia‐Yun, Chiou, Tzeon‐Jye, Liu, Chun‐Yu, Lin, Feng‐Chang, Lin, Jeong‐Shi, Hung, Man‐Hsin, Hsiao, Liang‐Tsai, Yen, Chueh‐Chuan, Gau, Jyh‐Pyng, Yen, Hsiu‐Ju, Hung, Giun‐Yi, Hsu, Hui‐Chi, Tzeng, Cheng‐Hwai, Liu, Jing‐Hwang, and Yu, Yuan‐Bin
- Subjects
- *
PROGENITOR cells , *STEM cell transplantation , *HEMATOLOGY , *ALGORITHMS , *LOGISTIC regression analysis , *STATISTICAL correlation , *TUMOR treatment , *ANTIGENS , *BIOTHERAPY , *DECISION trees , *HEMATOPOIETIC stem cells , *TUMORS , *RETROSPECTIVE studies - Abstract
Background: Enumerating hematopoietic progenitor cells (HPCs) by using an automated hematology analyzer is a rapid, inexpensive, and simple method for predicting a successful harvest compared with enumerating circulating CD34+ cells. However, the optimal HPC cutoff count and the indicating factors to be considered for improved predicting have not yet been determined.Study Design and Methods: Between 2007 and 2012, a total of 189 consecutive patients who proceeded to peripheral blood stem cell (PBSC) harvesting were retrospectively recruited. Baseline characteristics were analyzed to identify the risk factors for a failed harvest, which were defined as less than 2 × 10(6) CD34+ cells/kg. Variables identified by multivariate logistic regression and correlation analysis for predicting a successful harvest were subjected to classification and regression tree (CART) analysis.Results: PBSCs were successfully harvested in 154 (81.5%) patients. An age of at least 60 years, a diagnosis of a solid tumor, at least five prior chemotherapy cycles, prior radiotherapy, and mobilization with granulocyte-colony-stimulating factor alone or high-dose cyclophosphamide were independent baseline predictors of poor mobilization. In CART analysis, patients with zero to two host risk factors and either higher HPC (≥28 × 10(6) /L) or mononuclear cell (MNC; ≥3.5 × 10(9) /L) counts were categorized as good mobilizers and their harvest success rate was 92.3%. By contrast, 30.3% of harvests were adequate in the patients with three to five host risk factors and lower HPC and MNC counts.Conclusion: A CART algorithm incorporating host predictors and HPC and MNC counts improves predictions in a successful harvest and might reduce the necessity of monitoring peripheral CD34+ cells. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
32. Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation.
- Author
-
Liu, Yao-Chung, Chien, Sheng-Hsuan, Fan, Nai-Wen, Hu, Ming-Hung, Gau, Jyh-Pyng, Liu, Chia-Jen, Yu, Yuan-Bin, Hsiao, Liang-Tsai, Chiou, Tzeon-Jye, Tzeng, Cheng-Hwai, Chen, Po-Min, and Liu, Jin-Hwang
- Subjects
- *
GRAFT versus host disease , *DISEASE relapse , *HEMATOPOIETIC stem cell transplantation , *MORTALITY , *BLOOD diseases , *HEMATOLOGIC malignancies , *PROGNOSIS - Abstract
The cure of hematologic disorders by allogeneic hematopoietic stem cell transplantation (HSCT) is often associated with major complications resulting in poor outcome, including graft-versus-host disease (GVHD), relapse, and death. A novel composite endpoint of GVHD-free/relapse-free survival (GRFS) in which events include grades 3-4 acute GVHD, chronic GVHD requiring systemic therapy, relapse, or death is censored to completely characterize the survival without mortality or ongoing morbidity. In this regard, studies attempting to identify the prognostic factors of GRFS are quite scarce. Thus, we reviewed 377 adult patients undergoing allogeneic HSCT between 2003 and 2013. The 1- and 2-year GRFS were 40.8% and 36.5%, respectively, significantly worse than overall survival and disease-free survival (log-rank p<0.001). European Group for Blood and Marrow Transplantation (EBMT) risk score > 2 (p<0.001) and hematologic malignancy (p=0.033) were poor prognostic factors for 1-year GRFS. For 2-year GRFS, EBMT risk score > 2 (p<0.001), being male (p=0.028), and hematologic malignancy (p=0.010) were significant for poor outcome. The events between 1-year GRFS and 2-year GRFS predominantly increased in relapsed patients. With prognostic factors of GRFS, we could evaluate the probability of real recovery following HSCT without ongoing morbidity. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation.
- Author
-
Liu, Yao‐Chung, Chien, Sheng‐Hsuan, Fan, Nai‐Wen, Hu, Ming‐Hung, Gau, Jyh‐Pyng, Liu, Chia‐Jen, Yu, Yuan‐Bin, Liu, Chun‐Yu, Hsiao, Liang‐Tsai, Liu, Jin‐Hwang, Chiou, Tzeon‐Jye, and Tzeng, Cheng‐Hwai
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *PERICARDIAL effusion , *HOMOGRAFTS , *DISEASE incidence , *DIAGNOSIS , *THERAPEUTICS ,DISEASES in adults - Abstract
Pericardial effusion ( PE) is a rare but potentially life-threatening complication for allogeneic haematopoietic stem cell transplantation ( HSCT) recipients. The risk factors, aetiology, incidence and therapy are largely unclear. To investigate this issue, we reviewed 391 adult patients undergoing allogeneic HSCT between January 2003 and December 2013. Twelve out of 391 patients (3·1%) developed PE of moderate to large amounts, including 9 out of 12 patients (75%) identified as late-onset PE. Two out of the nine patients with late-onset PE experienced recurrent effusion. The median age at HSCT was 44·5 years (range: 22-63 years) among the 12 patients with PE and 47 years in the late-onset patients. Multivariate analysis revealed that multiple transplant procedures was a significant risk factor for PE ( P = 0·036) and a trend as risk factor in patients aged>50 years ( P = 0·066). For late-onset PE, pre-transplant age>50 years ( P = 0·032) and extensive chronic graft-versus-host disease ( cGVHD) ( P = 0·006) remained statistically significant on multivariate analysis. Currently, there are no published data exploring the risk factors for post-transplant PE in adult patients of allogeneic HSCT. Our study determined the risk factors and incidence for the post-transplant PE, especially in the late-onset group. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
34. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
- Author
-
Gau, Jyh-Pyng, Chen, Chih-Cheng, Chou, Yi-Sheng, Liu, Chia-Jen, Yu, Yuan-Bin, Hsiao, Liang-Tsai, Liu, Jin-Hwang, Hsu, Hui-Chi, Chiou, Tzeon-Jye, Chen, Po-Min, and Tzeng, Cheng-Hwai
- Subjects
- *
HAPLOTYPES , *JANUS kinases , *THROMBOCYTOSIS , *GENETIC mutation , *ALLELES - Abstract
The true frequency of the JAK2 46/1 haplotype in patients of myeloproliferative neoplasms (MPN) with CALR mutations was unknown. Totally 187 MPN cases with diagnosis of polycythemia vera (PV) and essential thrombocythemia (ET) were recruited. The frequency of 46/1 haplotype was significantly higher in JAK2V617F-positive PV (51%, p < 0.001) and ET (41%, p = 0.005) compared to normal controls. The exact location of JAK2V617F mutation was located at the cis-46/1 haplotype in 86.4% (32/37) PV patients and 87.5% (28/32) ET patients, respectively. Among the 51 patients of ET without JAK2V617F mutation, 38 (75%) patients harbored CALR mutations and 3 patients had MPL mutation. The frequency of 46/1 haplotype in the 38 ET patients with CALR mutations was 27%, which is not significantly different from that of normal control (p value = 0.879). Compared to non-46/1 haplotype, the presence of 46/1 haplotype had a trend to have higher white blood cell count in JAK2V617F-mutated PV and ET patients but not in CALR-mutated ET. We conclude that the 46/1 haplotype could have functioning effect but only in the context of JAK2V617F mutation. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
35. Absolute lymphocyte count and risk of short-term infection in patients with immune thrombocytopenia.
- Author
-
Hu, Ming-Hung, Yu, Yuan-Bin, Huang, Yu-Chung, Gau, Jyh-Pyng, Hsiao, Liang-Tsai, Liu, Jin-Hwang, Chen, Ming-Huang, Chiou, Tzeon-Jye, Chen, Po-Min, Tzeng, Cheng-Hwai, and Liu, Chun-Yu
- Subjects
- *
LYMPHOCYTE count , *IDIOPATHIC thrombocytopenic purpura , *LYMPHOPENIA , *LOGISTIC regression analysis , *MULTIVARIATE analysis , *IMMUNOSUPPRESSIVE agents , *THERAPEUTICS , *DISEASE risk factors - Abstract
Patients with immune thrombocytopenia (ITP) may be at increased risk of infection because of the steroids and other immunosuppressive agents used in its treatment. This study aimed to identify events that are associated with infection within 6 months of diagnosis and the impact that infection has on survival. We retrospectively evaluated 239 patients (107 men, 132 women; median age 61 years) diagnosed between January 1997 and August 2011. Every patient received steroid treatment according to the platelet count and the extent of bleeding. Logistic regression analysis was used to identify risk factors associated with the development of infection within 6 months of ITP being diagnosed. Sixty-two patients (25.9 %) developed an infection within 6 months of diagnosis. Multivariate analysis revealed that a lower absolute lymphocyte count (ALC) at diagnosis (<1 × 10/l) was an independent risk factor for infection ( P = 0.039; 95 % confidence interval, 1.033-3.599; odds ratio, 1.928). The time to infection event is significant shorter in those of low ALC, compared with those of higher ALC ( P = 0.032). Furthermore, the 1-year mortality rate after ITP diagnosis was significantly higher in those patients who developed an infection ( P = 0.001). ITP patients with a low absolute lymphocyte count at diagnosis have an increased risk of infection, and those who develop infections have lower 1-year survival. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
- Author
-
Lu, Hsueh-Ju, Huang, Yu-Chung, Liu, Chun-Yu, Hung, Man-Hsin, Hu, Ming-Hung, Wu, Chia-Yun, Hong, Ying-Chung, Hsiao, Liang-Tsai, Gau, Jyh-Pyng, Liu, Jin-Hwang, Hsu, Hui-Chi, Chiou, Tzeon-Jye, Tzeng, Cheng-Hwai, and Yu, Yuan-Bin
- Subjects
- *
B cells , *RITUXIMAB , *DIABETES , *LYMPHOMAS , *HEALTH outcome assessment , *CANCER chemotherapy , *CYCLOPHOSPHAMIDE - Abstract
Rituximab reforms the treatment of diffuse large B-cell lymphoma (DLBCL) and the prognostic significance of baseline patient features should be reevaluated. Few population-based studies have investigated the association of diabetes mellitus (DM) and outcomes of lymphoma; however, the results remain inconclusive. From January 1, 2000 to December 31, 2009, a total of 468 consecutive newly diagnosed DLBCL patients receiving first-line chemotherapy with cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP) or rituximab plus CHOP (R-CHOP) were enrolled. Pre-existing DM was defined according to medical history, use of antidiabetic medications, or any record of an abnormal hemoglobin A1c test. Progression-free survival (PFS) and overall survival (OS) were estimated and compared using the Kaplan-Meier method with a log-rank test. CHOP was administered in 194 patients, and 274 patients received R-CHOP. DM was identified in 16.2 % (76/468) of patients. Diabetic patients were older and more performance restricted, compared to the non-DM patients in both the CHOP and R-CHOP groups. In the CHOP group, 5-year PFS and OS were inferior in DM patients (PFS, 32.4 vs. 50.0 % ( P = 0.039); OS, 38.2 vs. 62.5 % ( P = 0.002)). However, outcomes were similar for both DM and non-DM patients in the context of R-CHOP treatment (PFS, 69.0 vs. 57.3 % ( P = 0.179); OS, 76.2 vs. 69.8 % ( P = 0.586)). The response rate of chemotherapy in DM patients was also improved to a level similar to non-DM patients with rituximab use. In conclusion, the prognostic significance of preexisting DM in DLBCL patients is changing in the rituximab era. The potentially additional benefit of rituximab in DM patients merits further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
37. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
- Author
-
Huang, Yu-Chung, Liu, Chun-Yu, Lu, Hsueh-Ju, Liu, Han-Tsung, Hung, Man-Hsin, Hong, Ying-Chung, Hsiao, Liang-Tsai, Gau, Jyh-Pyng, Liu, Jin-Hwang, Hsu, Hui-Chi, Chiou, Tzeon-Jye, Chen, Po-Min, Tzeng, Cheng-Hwai, and Yu, Yuan-Bin
- Subjects
- *
B cells , *LYMPHOMAS , *LYMPHOCYTE count , *RITUXIMAB , *CYCLOPHOSPHAMIDE , *DOXORUBICIN , *CANCER chemotherapy - Abstract
Several revisions of International Prognostic Index (IPI) have been proposed for patients with diffuse large B-cell lymphoma (DLBCL) after the introduction of rituximab. Expanding evidence suggests that baseline absolute lymphocyte count (ALC) is also an independent factor for outcome prediction. We investigated the optimal prognostic model for these patients in the rituximab era. The study enrolled 274 consecutive patients with DLBCL receiving first-line cyclophosphamide, doxorubicin, vincristine, and prednisone based chemotherapy with rituximab between 2003 and 2009. Five factors within IPI and ALC were entered for Cox regression analysis. Overall survival (OS) and progression-free survival were calculated for different risk groups of models. Efficacy of models was compared by the value of Akaike information criterion (AIC). Revised IPI (R-IPI) and ALC/R-IPI, but not IPI, were informative to discriminate between different risk groups. In multivariate analysis for individual factors of the prognostic models, performance status >1 [odds ratio (OR) 3.59], Ann Arbor stage III or IV (OR 2.24), and ALC <1 × 10/L (OR, 2.75) remained significant. Another modified score based on the three factors divided patients into four risk groups and the 3-year OS rate was 93, 77, 39, and 13 %, respectively. By comparing AIC values in the Cox proportional hazards model, the modified three-factor model was the superior prognostic model followed by established ALC/R-IPI, R-IPI, and standard IPI. In conclusion, the addition of the novel factor, ALC, interacts with other established factors in outcome prediction for DLBCL. Development of a new score is needed for a better risk stratification in the rituximab era and would be helpful in the design of future clinical trials. The proposed three-factor model should be validated in large-scale studies. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
38. Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage.
- Author
-
Chou, Yi‐Sheng, Gau, Jyh‐Pyng, Yu, Yuan‐Bin, Pai, Jih‐Tung, Hsiao, Liang‐Tsai, Liu, Jin‐Hwang, Hong, Ying‐Chung, Liu, Chun‐Yu, Yang, Ching‐Fen, Chen, Po‐Min, Chiou, Tzeon‐Jye, and Tzeng, Cheng‐Hwai
- Subjects
- *
HEMORRHAGE risk factors , *POLYCYTHEMIA vera , *THROMBOCYTOSIS , *LEUCOCYTOSIS , *MULTIVARIATE analysis - Abstract
Background Long-term outcomes are favorable for patients with polycythemia vera ( PV) and for patients with essential thrombocythemia ( ET). However, hemorrhage is a significant cause of morbidity and mortality in those patients. Methods We retrospectively recruited 247 patients who had received a diagnosis of PV ( n = 101) or ET ( n = 146) during the period 2001-2010. Results After a median follow-up period of 36.2 months, the cumulative incidence of hemorrhage was 39.6% in patients with PV (6.2% per person-year) and 29.7% in patients with ET (5.9% person-years). Episodes of major bleeding occurred in 9.9% of patients with PV and in 14.4% of patients with ET. Overall survival was significantly shorter among patients with hemorrhage than among those without said complication ( P < 0.001 for overall patients; P = 0.002 for patients with PV; P = 0.026 for patients with ET). In the univariate analysis, age ≥60 yr ( OR: 4.77, P = 0.046) and WBC ≥ 16 × 109/L ( OR: 4.15, P = 0.010) were predictors of hemorrhage in patients with PV, and age ≥60 yr ( OR: 3.25, P = 0.040), WBC ≥ 16 × 109/L ( OR: 2.89, P = 0.024), albumin <4.0 g/dL ( OR: 4.10, P = 0.002), and splenomegaly ( OR: 5.19, P = 0.002) were predictors of hemorrhage in patients with ET. Multivariate analysis showed that WBC ≥ 16 × 109/L was the only significant risk factor for hemorrhage in patients with PV ( OR: 3.51, P = 0.026) and that splenomegaly was the only risk factor for hemorrhage in patients with ET ( OR: 3.00, P = 0.048). Conclusion Leukocytosis in PV and splenomegaly in ET are independent risk factors for hemorrhage. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
39. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
- Author
-
Hung, Man-Hsin, Yu, Yuan-Bin, Huang, Yu-Chung, Liu, Han-Tsung, Hong, Ying-Chung, Hsiao, Liang-Tsai, Liu, Jin-Hwang, Gau, Jyh-Pyng, Chiou, Tzeon-Jye, Chen, Po-Min, Tzeng, Cheng-Hwai, and Liu, Chun-Yu
- Subjects
- *
B cell lymphoma , *LYMPHOCYTE count , *AUTOTRANSPLANTATION , *STEM cell transplantation , *RITUXIMAB , *HEALTH outcome assessment , *CANCER chemotherapy , *CYCLOPHOSPHAMIDE - Abstract
Certain portions of patients with diffuse large B cell lymphoma (DLBCL) do not achieve a complete remission after first-line rituximab combining chemotherapy. This retrospective study aimed to characterize the outcome of patients with DLBCL that achieved partial remission or had stable disease after first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone). The effects of subsequent treatments and factors associated with event-free survival (EFS) after second-line treatments were analyzed. A total of 103 patients were enrolled and 81 (76.8 %) patients received intensive chemotherapy, whereas the others (23.2 %) received either palliative chemotherapy or supportive care post first-line treatment. Patients receiving intensive chemotherapy had significantly higher EFS (median 7.9 months) than the others; 28 (34.6 %) patients in this group received autologous stem cell transplantation (ASCT), which may have further improved the EFS. An International Prognostic Index (IPI) >2 and absolute lymphocyte count (ALC) at diagnosis <1,000/UL were significant prognostic factors associated with worse EFS. The survival advantage of ASCT remained significant after adjustment for these factors. The results suggest intensive chemotherapy plus ASCT may provide modest disease control in patients with DLBCL who achieve PR or SD to first-line R-CHOP, particularly in those with a higher IPI score and/or low ALC at diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
40. Large pericardial effusion as a life-threatening complication after hematopoietic stem cell transplantation-association with chronic GVHD in late-onset adult patients.
- Author
-
Liu, Yao-Chung, Gau, Jyh-Pyng, Hong, Ying-Chung, Yu, Yuan-Bin, Hsiao, Liang-Tsai, Liu, Jin-Hwang, Chiou, Tzeon-Jye, Chen, Po-Min, and Tzeng, Cheng-Hwai
- Subjects
- *
PERICARDIAL effusion , *HEMATOPOIETIC stem cell transplantation , *CARDIAC tamponade , *GRAFT versus host disease , *PATHOLOGICAL physiology , *HEART function tests , *RETROSPECTIVE studies , *PATIENTS - Abstract
Large pericardial effusion (LPE) with cardiac tamponade is a rare but life-threatening complication in adults undergoing hematopoietic stem cell transplantation (HSCT). The incidence and pathophysiology have not been well defined. We retrospectively reviewed 601 patients (≧18 years of age) receiving HSCT (262 autologous, 189 siblings, and 150 unrelated donors) in our center from January 2001 to September 2011. We described the incidence, clinical characteristics, treatment, and outcome. In total, six patients (0.998 %) developed seven episodes (1.16 %) of LPEs with cardiac tamponade. One patient underwent unrelated allografts and the other five patients received sibling allografts. The median day of detecting LPE were 176 in the six patients and 241 in the four late-onset patients (range, 9-369). All patients had normal cardiac function before HSCT. Two patients developed LPE early after conditioning, considered as cardiac toxicity resulting from high-dose cyclophosphamide. Four patients had chronic graft-versus-host disease (GVHD) involving lung, skin and sicca syndrome concomitant with or preceding the development of LPE. All episodes of cardiac tamponade were effectively managed by pericardiocentesis and enhanced immunosuppression. In conclusion, LPE and cardiac tamponade may develop after allogeneic HSCT, either with sibling or matched unrelated donor. The etiology is probably related to chronic GVHD in cases of late onset. Emergent pericardiocentesis and enhanced immunosuppression can effectively control this life-threatening complication. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
41. Pre-existing diabetes mellitus in patients with multiple myeloma.
- Author
-
Chou, Yi-Sheng, Yang, Ching-Fen, Chen, Harn-Shen, Yang, Sheng-Hsiang, Yu, Yuan-Bin, Hong, Ying-Chung, Liu, Chun-Yu, Gau, Jyh-Pyng, Liu, Jin-Hwang, Chen, Po-Min, Chiou, Tzeon-Jye, Tzeng, Cheng-Hwai, and Hsiao, Liang-Tsai
- Subjects
- *
MULTIPLE myeloma , *DIABETES , *HYPERGLYCEMIA , *SERUM , *CREATININE , *DIPHOSPHONATES , *PATIENTS - Abstract
Objectives Type 2 diabetes mellitus is present in approximately 10% of patients at diagnosis of multiple myeloma ( MM) and is associated with increased risks of adverse events caused by novel antimyeloma agents. However, the impact of type 2 diabetes on the survival of patients with MM has not been studied. Methods We enrolled newly diagnosed patients with MM in Taipei Veterans General Hospital between 1999 and 2007 and identified those with pre-existing diabetes. The impact of pre-existing diabetes on patients with MM was evaluated by comparing clinical features, treatments and adverse reactions related to glycaemic control and overall survival ( OS) of patients with and without pre-existing diabetes. Results Of 310 patients with MM, 73% were men and 40 (12.9%) had pre-existing diabetes. Compared with their non-diabetic counterparts, MM patients with pre-existing diabetes had a significantly higher proportion of renal impairment [( RI), serum creatinine ≥2.0 mg/ dL] and International Staging System stage III at diagnosis, and a significantly lower proportion of bisphosphonate use and a lower rate of RI reversal ( P = 0.087). During the course of the disease, hyperglycaemia and hypoglycaemia of any grade were noted in 23 (67.6%) and 6 (17.6%) of these patients, respectively. Antidiabetic therapy was changed in 10 (29.4%) of 34 evaluable patients. MM patients with pre-existing diabetes had a significantly higher all-cause mortality risk (hazard ratio, 1.509; 95% confidence interval, 1.023-2.225, P = 0.037) compared with their non-diabetic counterparts. Conclusions Our study demonstrated the impact of pre-existing diabetes on clinical features and OS in patients with MM. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
42. Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification.
- Author
-
Liu, Chia-Jen, Hong, Ying-Chung, Yang, Ching-Fen, Liu, Shih-Hao, Gau, Jyh-Pyng, Liu, Jin-Hwang, Hsiao, Liang-Tsai, Liu, Chun-Yu, Yu, Yuan-Bin, and Tzeng, Cheng-Hwai
- Subjects
- *
MYELODYSPLASTIC syndromes , *LEUKEMIA , *BONE marrow diseases , *SYNDROMES - Abstract
We report 67 patients with acute erythroid leukemia (erythroleukemia) based on the World Health Organization (WHO) 2008 classification. Reviewing the clinicopathologic features, cytogenetics and outcomes, the characteristics of erythroleukemia resembled myelodysplastic syndromes (MDS). Patients with poor performance status, advanced anemia and poor-risk cytogenetics had significantly inferior outcomes. The International Prognostic Scoring System (IPSS) for MDS is useful to differentiate the prognosis of erythroleukemia. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
43. International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents.
- Author
-
Yang, Sheng-Hsiang, Teng, Hao-Wei, Hong, Ying-Chung, Liu, Chun-Yu, Yu, Yuan-Bin, Yang, Ching-Fen, Gau, Jyh-Pyng, Liu, Jin-Hwang, Chang, Tai-Jay, Yen, Jeffrey, Chen, Po-Min, Chiou, Tzeon-Jye, Tzeng, Cheng-Hwai, and Hsiao, Liang-Tsai
- Subjects
- *
TREATMENT effectiveness , *MYELOMA proteins , *MEDICAL care , *THALIDOMIDE , *LABORATORY test panels - Abstract
The applicability of the International Staging System (ISS) for Chinese patients with multiple myeloma (MM) has not been demonstrated, especially with respect to treatments with novel agents. Newly diagnosed MM patients at Taipei Veterans General Hospital were enrolled between 1996 and 2007. Data regarding clinical features, laboratory tests, and outcome at last follow-up were collected. A total of 389 MM patients (71% male) were enrolled, with median age of 71 years. At diagnosis, 72.7% had Durie-Salmon (DS) stage III disease, 56.2% had ISS stage III disease, and 34% had serum creatinine ≧2.0 mg/dL. Compared with patients diagnosed in the first calendar period 1996-2001, the patients of the second calendar period 2002-2007 were older and more of these patients had received novel agents, especially thalidomide. The median overall survival period was 20.5 months, with a significant increase of patients in the second calendar period (15.3 and 28.2 months, respectively; P = 0.002), especially for those with ISS stages I and II. In the Cox proportion model, elevated serum β microglobulin at diagnosis (≧3.5 mg/L), old age (≧65 years), and impaired renal function were found to be independently associated with poor survival. Over the entire period, the ISS was found to be effective in providing an accurate prognosis with respect to different ages and calendar periods. This is the first study to show the applicability of ISS for Chinese patients with MM, especially for those who had received thalidomide. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
44. Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience.
- Author
-
Lin, Han-Nan, Liu, Chun-Yu, Hong, Ying-Chung, Pai, Jih-Tung, Yang, Ching-Fen, Yu, Yuan-Bin, Hsiao, Liang-Tsai, Chiou, Tzeon-Jye, Liu, Jin-Hwang, Gau, Jyh-Pyng, Tzeng, Cheng-Hwai, and Chen, Po-Min
- Subjects
- *
T-cell lymphoma , *PROGNOSIS , *DRUG therapy , *LACTATE dehydrogenase , *CYCLOPHOSPHAMIDE , *ANTHRACYCLINES , *MULTIVARIATE analysis - Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis. This study retrospectively analyzed patients with AITL from a single institution in Taiwan, aiming to define the clinical features and prognostic factors. Patients with AITL treated at our institution from February 1988 through January 2010 were enrolled. Factors associated with overall survival (OS) were determined by statistical methods. A total of 31 Taiwanese patients (21 males) were identified. The median age was 74 years (range, 27-90). Among all patients, 67.7% were Ann Arbor stage III or IV, 58.1% presented with B symptoms, 48.4% had hypoalbuminenia (<35 g/L), and 63.3% had elevated lactate dehydrogenase (LDH) at diagnosis. First-line chemotherapy was mostly CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisolone)-based and complete response (CR) was achieved in 25% of patients. The actuarial 2-year survival rate was 38.7%, and the median OS was 14.9 months. In multivariate analysis, initial presentation with fever ( p = 0.035), advanced stage ( p = 0.024), and failure to achieve CR ( p = 0.029) were independent adverse factors associated with poorer OS. Interestingly, OS did not differ whether chemotherapy regimens contained anthracycline or not. Taiwanese patients with AITL were usually elderly. Despite the prognosis being generally poor, patients with AITL should be treated with the goal of achieving CR, regardless of anthracycline- or non-anthracycline-based chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
45. High Prevalence of SV40 Infection in Patients with Nodal Non-Hodgkin's Lymphoma But Not Acute Leukemia Independent of Contaminated Polio Vaccines in Taiwan.
- Author
-
Chen, Po-Min, Yen, Chueh-Chuan, Yang, Muh-Hwa, Poh, Say-Bee, Hsiao, Liang-Tsai, Wang, Wei-Shu, Lin, Peng-Chan, Lee, Ming-Yang, Teng, Hao-Wei, Bai, Li-Yuan, Chu, Chiau-Jun, Chao, Shu-Chauo, Yang, An-Hang, Chiou, Tzeon-Jye, Liu, Jin-Hwang, and Chao, Ta-Chung
- Subjects
- *
SV40 (Virus) , *SIMIAN viruses , *LEUKEMIA , *LYMPH nodes , *DISEASE risk factors - Abstract
Recent studies have linked simian virus 40 (SV40) to non-Hodgkin's lymphoma (NHL), especially in countries in which people were exposed to contaminated polio vaccines prior to 1963. In Taiwan, nearly all children were not exposed to contaminated polio vaccine during this period; the relationship between SV40 infection and hematological malignancies is unclear and deserves to be studied. Using PCR amplification of SV40 large T antigen DNA, confirmed by Southern blot hybridization and sequence analysis, 91 frozen lymph nodes from NHL patients were examined. Thirteen (14.3 percent) showed positive for SV40. All other test samples, including diagnostic bone marrow from patients with acute leukemia, peripheral blood from 10 relatives of SV40 positive-patients and 91 age-matched normal volunteers, and 5 reactive hyperplastic lymphoid tissues, showed negative. These results may reflect that human-to-human transmission of SV40 is independent of contaminated polio vaccines; and SV40 is possibly associated with the development of NHL in Taiwan (p = 0.0001). Prospective studies are needed to determine the prevalence of SV40 infections in our and other human populations and to explore the means of transmission of the virus. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
46. A solitary pulmonary lymphomatoid granulomatosis-like lesion as the only manifestation of post-transplant lymphoproliferative disorder after hematopoietic stem-cell transplantation.
- Author
-
Yang, Sheng-Hsiang, Yeh, Yi-Chen, Chan, Yu-Jiun, Chou, Teh-Ying, and Hsiao, Liang-Tsai
- Subjects
- *
LETTERS to the editor , *STEM cell transplantation - Abstract
A letter to the editor is presented regarding a case study on the development of lymphomatoid granulomatosis (LYG)-like lesion, a post-transplant lymphoproliferative disorder in a 47-year-old female with aplastic anemia who underwent allogeneic hematopoietic stem-cell transplantation (HSCT).
- Published
- 2011
- Full Text
- View/download PDF
47. Nasopharyngeal Lymphoma: A 22-Year Review of 35 Cases.
- Author
-
Hsueh, Chien-Yu, Yang, Ching-Fen, Gau, Jyh-Pyng, Kuan, Edward C., Ho, Ching-Yin, Chiou, Tzeon-Jye, Hsiao, Liang-Tsai, Lin, Ting-An, and Lan, Ming-Ying
- Subjects
- *
MUCOSA-associated lymphoid tissue lymphoma , *MANTLE cell lymphoma , *LYMPHOMAS , *LYMPHOPROLIFERATIVE disorders , *NON-coding RNA - Abstract
Nasopharyngeal (NP) lymphoma is a rare primary malignancy of the head and neck and represents a minority of malignancies originating from the nasopharynx. For this reason, there are limited data regarding epidemiologic and treatment outcomes. This is a retrospective review of patients diagnosed with NP lymphoma from 1995 to 2017 at a tertiary medical center. The patients' demographic data, clinical presentations, treatment modalities, Epstein–Barr virus (EBV)-encoded small RNA (EBER) staining, and outcomes were investigated. We considered a total of 35 patients, including 20 males and 15 females, diagnosed with NP lymphoma. The age ranged from 17 to 88 years (mean = 59.6). The common presentations were nasal obstruction, epistaxis, and neck mass. In our study, the most common pathological diagnosis of NP lymphoma was diffuse large B cell lymphoma (DLBCL) (n = 17), followed by NK/T cell lymphoma (NKTCL) (n = 9). Other pathologic diagnoses included extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALToma), small lymphocytic lymphoma, mantle cell lymphoma. There were 13 cases showing EBER positivity, including 7 cases of NKTCL, 5 cases of DLBCL, and 1 case of post-transplant lymphoproliferative disorder (PTLD). Most patients received chemotherapy alone, while some patients received both chemotherapy and radiotherapy. Seven patients had local recurrence, and fewer than half of the patients (n = 16) were alive at the time of the study (mean follow-up duration: 54.4 months). The five-year overall survival was 50.4%. NP lymphoma is very rare, and the most common pathologic type is DLBCL. EBER positivity is found in both NKTCL and DLBCL. Identifying more effective therapeutic agents is extremely important to improve patients' survival. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
48. Risk factors and clinical features for post-transplant thoracic air-leak syndrome in adult patients receiving allogeneic haematopoietic stem cell transplantation.
- Author
-
Liu, Yao-Chung, Chou, Yi-Hsin, Ko, Po-Shen, Wang, Hao-Yuan, Fan, Nai-Wen, Liu, Chia-Jen, Hsiao, Liang-Tsai, Chien, Sheng-Hsuan, Chiou, Tzeon-Jye, Liu, Jin-Hwang, and Gau, Jyh-Pyng
- Subjects
- *
DISEASE risk factors , *THORACIC outlet syndrome , *STEM cell transplantation , *MULTIVARIATE analysis , *GRAFT versus host disease , *MYCOSES - Abstract
Post-transplant thoracic air-leak syndrome (ALS) is rare but potentially life-threatening in patients receiving allogeneic haematopoietic stem cell transplantation (HSCT). Nevertheless, papers on thoracic ALS are limited, and this complication remains largely unknown. We reviewed 423 adult patients undergoing allogeneic HSCT from 2003 to 2014. Risk factors, clinical features and survival for thoracic ALS were collected and analysed. Thirteen out of 423 patients (3.1%) developed post-transplant thoracic ALS, including two ALS patients in the early phase. The median age at HSCT was 33 years among 13 patients with thoracic ALS. Male patients were predominant (69%). The median onset time was 253 days (range: 40–2680) after HSCT. Multivariate analysis revealed that grade III–IV acute graft-versus-host disease (GVHD) (p = 0.017), extensive chronic GVHD (cGVHD) (p = 0.019) and prior history of pulmonary invasive fungal infection (p = 0.007) were significant risk factors for thoracic ALS. In patients with cGVHD, those with thoracic ALS had a significantly worse survival than those without thoracic ALS (p = 0.04). Currently, published data analysing and exploring post-transplant thoracic ALS are limited. Our study employed a large patient cohort and determined the risk factors and clinical features for post-transplant thoracic ALS. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
49. Correction: Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.
- Author
-
Chen, Chien-Ting, Liu, Chun-Yu, Yu, Yuan-Bin, Liu, Chia-Jen, Hsiao, Liang-Tsai, Gau, Jyh-Pyng, Chiou, Tzeon-Jye, Liu, Jing-Hwang, and Liu, Yao-Chung
- Subjects
- *
GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *LIVER diseases - Published
- 2018
- Full Text
- View/download PDF
50. Splenic artery pseudoaneurysm with rupture by transformed splenic marginal zone B cell lymphoma.
- Author
-
Huang, Yu-Chung, Xie, Zhi-Yi, Tseng, Hsiou-Shan, Yang, Ching-Feng, and Hsiao, Liang-Tsai
- Subjects
- *
SPLENIC artery , *FALSE aneurysms , *LYMPHOMA diagnosis , *ABDOMINAL pain , *B cells , *DISEASES - Abstract
The article presents a case study of an 88-year-old patient who was admitted due to persistent severe pain on his abdomen. Findings of his examinations showed a marked splenomegaly with relative high attenuation areas and a pseudoaneurysm in splenic artery. He was diagnosed with splenic marginal zone B cell lymphoma and died two months after.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.